Capstan Therapeutics Co-Founder Drew Weissman, M.D., Ph.D., Awarded Nobel Prize in Physiology or Medicine for Enabling Rapid Development of RNA-based COVID-19 Vaccine
Retrieved on:
Monday, October 2, 2023
Health, Genetics, COVID-19, Research, Science, Pharmaceutical, Biotechnology, Nobel Prize, Partnership, University, Infection, Capstan equation, Cell, Messenger, Neurosurgery, ARD International Music Competition, Nobel Prize in Physiology or Medicine, Therapy, Medicine, Disease, Pharmaceutical industry, Vaccine, Capstan, Physiology
Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced that the Company’s Co-Founder Drew Weissman, M.D., Ph.D., was awarded the 2023 Nobel Prize in Physiology or Medicine for his discoveries in nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.
Key Points:
- Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced that the Company’s Co-Founder Drew Weissman, M.D., Ph.D., was awarded the 2023 Nobel Prize in Physiology or Medicine for his discoveries in nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.
- Dr. Weissman shares the award with his research collaborator of many years, Katalin Karikó, Ph.D., an adjunct professor of neurosurgery at the University of Pennsylvania.
- “It has been a privilege to work with Dr. Weissman and our other collaborators on the founding technology for Capstan which was made possible by his many years of work on mRNA biology and delivery leading up to the Nobel Prize,” said Dr. Haig Aghajanian, Capstan Co-Founder and Vice President of Research.
- “It’s been so rewarding to work side-by-side with him.”
“All of the Capstaneers congratulate Dr. Weissman and Dr. Karikó on receiving the 2023 Nobel Prize in Physiology or Medicine for their visionary research in unlocking the power of mRNA-based therapeutics,” said Dr. Laura Shawver, President and Chief Executive Officer of Capstan.